Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00431756 · ClinicalTrials.gov registry record

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

A clinical trial of Barrett Esophagus and Gastroesophageal Reflux, sponsored by Johns Hopkins University.

Active
Registry status
600
Enrollment target
1
Study location

NCT00431756 is a study of Barrett Esophagus and Gastroesophageal Reflux that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 600 participants, below the 3,547-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00431756, a study of Barrett Esophagus and Gastroesophageal Reflux, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
600 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2002-05-01
Est. Completion 2026-06-01

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT00431756

The ClinicalTrials.gov registry entry for NCT00431756 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,547-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (83% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Barrett Esophagus appearing as the primary indexed condition, and to 0 interventions.

NCT00431756 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00431756 about?

NCT00431756 is a clinical study titled "Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus". The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

What is the current status of trial NCT00431756?

This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2002-05-01. Estimated completion is 2026-06-01.

What conditions does trial NCT00431756 study?

This clinical trial studies the following conditions: Barrett Esophagus, Gastroesophageal Reflux, Esophageal Neoplasm.

Who is sponsoring clinical trial NCT00431756?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00431756 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.